Molecular Partners AG - ADR opened lower at $3.05, compared with its previous close of $3.09. In the last trading session, the stock traded between $3.00 and $3.01. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Molecular Partners AG - ADR is now worth
$ 20.49
Resulting in a loss of
$ 79.51 (79.51%)
Note: Past profits do not guarantee future returns.
Rating from 3 Analysts
Today's Change
$-0.09 (-2.91%)
Day High
$3.01
Day Low
$3.00
Day Open
$3.05
Prev Close
$3.09
Volume
687
1W Return
-6.57%
1M Return
-21.26%
3M Return
-27.18%
6M Return
-27.36%
1Y Return
-25.56%
Market Cap ($ Mn)
121
PE Ratio
-
PB Ratio
2.38
PEG Ratio
-
ROE
-55.81%
ROCE
-54.19%
EPS (TTM)
$-0.31
1 Week
-6.57%
1 Month
-21.26%
3 Months
-27.18%
6 Months
-27.36%
9 Months
-35.48%
Molecular Partners MP0632 preclinical data shows no healthy cell impact
Preclinical data shows no detectable impact on healthy mesothelial or epithelial cells. Logic-gated Switch-DARPin design enables selective cytotoxicity against co-expressing TAAs. Favorable safety profile supports IND-enabling studies for MSLN and EpCAM solid tumors.
6 days agoMolecular Partners to present MP0712 clinical data at two 2026 conferences
Molecular Partners will present MP0712 data at SNMMI Theranostics and NACLC 2026. SNMMI oral presentation scheduled for Nov 7, 2026, focusing on target expression. NACLC poster on Dec 5, 2026, will show initial Phase 1/2a dose escalation data. MP0712 targets DLL3 in small cell lung cancer using Lead-212 radioisotope.
7 days agoMolecular Partners Q2 EPS loss of $(0.89) misses estimates
Molecular Partners Q2 EPS loss of $(0.89) missed the $(0.45) estimate. The miss represents a 95.56% deviation from analyst consensus. Losses widened 31.34% YoY from $(0.67) per share in Q2FY25.
2mo agoMolecular Partners net loss narrows to CHF 26.7m in H1FY26
Net loss narrows to CHF 26.7m in H1FY26 from CHF 37.2m in prior year. Cash position stands at CHF 67.9m as of June 30, 2026. Operating expenses fall to CHF 27.0m due to lower restructuring costs. Headcount reduces to 116.7 FTEs from 153.0 FTEs in H1 2025. Lead candidate MP0712 advances to dose level 2 in Phase 1/2a study.
2mo agoMolecular Partners advances Phase 2 TACTIC trial of MP0317
Molecular Partners AG initiated a randomized Phase 2 proof-of-concept study of MP0317 combined with chemoimmunotherapy for first-line advanced biliary tract carcinoma. The TACTIC study targets 75 patients across nine sites in France, comparing the MP0317 combination against standard-of-care alone. Data updates are anticipated in 2027, with trial completion in 2028, following positive Phase 1 results showing tumor-localized CD40 activation.
4mo agoMolecular Partners and Orano Med dose first patients in MP0712 trial
Molecular Partners AG and Orano Med have dosed the first patients in a Phase 1/2a trial of MP0712, a Radio-DARPin targeting DLL3 for small cell lung cancer. The trial uses a matched-pair diagnostic approach to predict tumor uptake before treatment. Initial data is expected in 2026, with comprehensive results in 2027.
4mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Molecular Partners AG - ADR is now worth
$ 20.49
Resulting in a loss of
$ 79.51 (79.51%)
Note: Past profits do not guarantee future returns.
